Alendronate affects osteoprotegerin/receptor of nuclear factor κB-ligand activator expression in human bone marrow stroma cells in vitro
WANG Jian-zhong,WANG Kun-zheng,ZHOU Rong-xing,LI Xiao-dong,GUO Jun,YANG Tie-yi
DOI: https://doi.org/10.3877/cma.j.issn.1674-134X.2011.05.014
2011-01-01
Abstract:Objective To evaluate the effects of alendronate on osteoprotegerin(OPG) and receptor of activator of nuclear factor κB-ligand(RANKL) expression in human bone marrow stroma cells(BMSCs) in vitro,and to investigate the related mechanisms of alendronate on prevention and treatment for osteoporosis.Methods 10ml bone marrow was taken at anterior superior iliac spine from 24 healthy male volunteers aged 20-30 years.BMSCs were isolated,cultured in vitro,and randomly divided into four groups: high,middle,low dose alendronate groups and control group.In high,middle and low dose groups,hMSCs culture fluid contained 1× 10-7mol/L,1× 10-8mol/L,1×10-9mol/L alendronate respectively.In control group,there was no special treatment but cultured hMSCs in LG-DMEM.Two weeks after treatment,the expressions of OPG and RANKL were evaluated by RT-PCR and Western blot.Results In RT-PCR,the ratios of OPG/RANKL in high,middle,low dose alendronate groups and control group were(8.77±1.16),(6.68±1.25),(4.86±0.79) and(0.58±0.13) respectively.In Western blot,the ratios of OPG/RANKL in high,middle,low dose alendronate groups and control group were(1.18±0.47),(1.09±0.56),(0.82±0.32) and(0.25±0.12) respectively.The ratio of OPG/RANKL was higher in alendronate group than it in control group(P<0.01),but there was no significant difference in three alendronate groups.Conclusion Alendronate may enhance OPG expression and inhibit RANKL expression of hMSCs in vitro.